Introduction Impact of treatment and prognostic indicators of outcome are relatively ill-defined in esthesioneuroblastomas (ENB) because of the rarity of these tumors. This study was undertaken to assess the impact of craniofacial resection (CFR) on outcome of ENB. Patients and Methods Data on 151 patients who underwent CFR for ENB were collected from 17 institutions that participated in an international collaborative study. Patient, tumor, treatment, and outcome data were collected by questionnaires and variables were analyzed for prognostic impact on overall, disease-specific and recurrence-free survival. The majority of tumors were staged Kadish stage C (116 or 77%). Overall, 90 patients (60%) had received treatment before CFR, radiation therapy in 51 (34%), and chemotherapy in 23 (15%). The margins of surgical resection were reported positive in 23 (15%) patients. Adjuvant postoperative radiation therapy was used in 51 (34%) and chemotherapy in 9 (6%) patients.
Although esthesioneuroblastoma (ENB) is a relatively uncommon neoplasm of the nasal vault, this tumor has generated considerable interest in recent medical literature due to several controversies related to the cell of origin, histologic diagnosis, clinical behavior and staging, treatment, and outcomes. 1, 2 Central to these controversies is the fact that ENB belong to a spectrum of malignant tumors with neuroendocrine differentiation which has resulted in diversity in reporting clinical behavior. 3, 4 The advent of immunohistochemical staining (IHC) and electron microscopy (EM) have improved classification of this group of tumors, and a recent report has in fact documented the high rate of reclassification of "ENB" when examined by an experienced pathologist using IHC and EM. 5, 6 This observation is of particular significance in evaluating the clinical behavior and results of treatment reported in the literature. In spite of the controversies surrounding management of ENB, there is a little doubt that combined modality treatment using surgical resection and radiation therapy provides the best results in terms of control of disease and survival. Until craniofacial resection (CFR) became available as surgical treatment for ENB, 7 extracranial transfacial approaches have been standard for surgical resection. The use of CFR in management of ENB has been documented to improve outcomes not only as evidenced by the comparison of recent reports with historical reports, but also at the same institution over time. 8 Most reports in the literature however, are based on a small number of patients treated over a long period of time with varying treatment regimens. Identification of independent prognostic predictors using multivariate analysis has therefore not been possible. The purpose of this study was to evaluate the efficacy of CFR in a multi-institutional international cohort of a large number of patients with ENB.
We were also able to analyze this cohort in multivariate analysis to identify independent predictors of outcome after CFR.
Patients and Methods
A multi-item questionnaire was sent out to 17 participating investigators from various parts of the world to obtain information on patient, tumor, treatment variables, and outcomes of treatment. Completed data sheets on patients treated between October 1956 and January 2000 were submitted by each investigator to the central analyzing office for data entry, compilation, and statistical analysis.
Data Entry, Patient Exclusions, and Statistical Methods
Data were entered into a commercially available spreadsheet (Microsoft Excel 2000, Microsoft Corporation) and statistical analysis was performed using a computerized software package (JMP version 4.0, SAS Institute Inc., Cary, NC). The total number of patients collected from all contributors was 1541. Of these, 114 had to be excluded either because of no information on pathology (n ¼ 26) or lack of follow-up data (n ¼ 88). After these exclusions, a total of 1427 patients were eligible for analysis. Of the 1427 analyzable patients, 120 had benign tumors and have been excluded in this analysis. We have previously reported the results of CFR in the 1307 patients with malignant tumors of the skull base 9 and this report focuses on the 151 patients from this group who had the histological diagnosis of ENB. The follow-up interval was calculated in months from the date of CFR to the date of last follow-up or death and recurrence-free interval was calculated from the date of CFR to that of first recurrence. For disease-specific survival, patients who reportedly died of non-cancer-related causes (7/151 or 4.6%) and those who were alive with disease at last follow-up (16/ 151 or 10.6%) were censored. Recurrence-free (RFS), overall (OS), and disease-specific (DSS) survival rates were calculated using the Kaplan-Meier method and univariate comparisons between groups were performed using the log-rank test. A p value of 0.05 or less was considered significant and significant factors were entered into multivariate analysis using the Cox proportional hazards model. Nonparametric qualitative and quantitative comparisons were performed using the Fisher exact test and Mann-Whitney U test, respectively.
Patient Demographics
Patients ranged in age from 12 to 82 years with a median of 49.5 years. ►Table 1 presents the demographic data on these patients.
Primary Tumor
The anatomic extent of the primary tumor is listed in ►Table 2. The Kadish stage was directly reported by the contributors in only 36 of the 151 patients (23.8%). A total of 133 patients (74.8%) could be retrospectively staged based on available information on orbital and intracranial extent while 2 (1.3%) lacked sufficient information for staging. No orbital or intracranial involvement was reported in 33 patients, but details on anatomic extent of tumor were not precise enough to stratify them into Kadish stage A and B. This group was therefore analyzed as Kadish stage A/B.
Treatment
Most patients had undergone some form of treatment before CFR (►Table 3). The details of prior radiation therapy were available in 49 patients (96%), and the dose ranged from 1800 to 9000 cGy with a median of 5000 cGy. Adjuvant postoperative radiotherapy was used in 71 patients (47%); a median dose of 5870 cGy was administered (range: 2800 to 6200 cGy). Adjuvant chemotherapy was used in nine patients (5.9%) (►Table 4).
Follow-Up
The follow-up interval ranged from 1 to 323 months with a median of 56 months. The period of follow-up was less than 5 years in 92 patients (61%) while 59 patients (39%) were followed up for longer than 5 years. Of the 117 patients who were alive, 52 (44.4%) had a longer than 5-year follow-up.
Results
►Table 5 lists the details of surgical excision, reconstruction, and margin status. Overall, 32.5% of patients were recorded to have developed a postoperative complication (►Table 6). The commonest complications were related to the central nervous system or local wound while the postoperative mortality rate was 1.3%. With a median follow-up of 56 months (range: 1 to 323 months), the 5-year OS and DSS rates calculated using the Kaplan-Meier method were 77.7 and 82.6%, respectively (►Fig. 1). The median time to recurrence after CFR was 16 months (1 to 140 months) and the 5-year RFS was 64.2%. The majority of the 106 patients (84/106 or 79.2%) who were recurrence-free had been followed up for an interval (median 46 months) longer than the median time to recurrence.
On multivariate analysis, intracranial extension of the disease, and close or positive margins of surgical excision were the only independent predictors of worse DSS (►Table 7) and OSS (►Table 8). Intraorbital extension of tumor was an additional independent predictor of RFS (►Table 9). Kadish stage was analyzed in a multivariate model that did not include intraorbital and intracranial extension, and was not an independent predictor of any of the three outcomes.
Discussion
Existing reports on ENB from individual institutions are based on small numbers of patients since the tumor is uncommon. As with other uncommon tumors, reporting outcomes becomes difficult and patients treated over long periods of time have to be studied to accumulate reasonable numbers. This introduces heterogeneity in the study population because diagnostic and therapeutic modalities evolve with time. Additionally, for a tumor such as ENB, there has been a major evolution in histological diagnosis with the realization that ENB belongs to a spectrum of neuroendocrine tumors that have varying clinical behavior. If all of these issues are taken into account, it is not surprising that there is considerable difficulty in comparing reported series which adds to the confusion regarding the clinical behavior, treatment, and outcomes in ENB.
Histologic features of ENB have been used for prognostic prediction in Hyam's classification. [10] [11] [12] [13] Although the differential diagnosis has been facilitated by modern technology, it is important to remember that ENB does not have a unique, pathognomonic immunophenotype; rather one must, in conjunction with the morphological appearance, interpret a panel of antibody reactivity, which can be variable. For instance, epithelial membrane antigen (EMA) is generally negative in ENB, whereas up to 65% of SNUC will stain positively.
14 S-100 protein should only stain in a sustentacular-type pattern in ENB; not staining the majority of tumor cells, as one would expect in a melanoma, for instance. Neuron-specific enolase is almost always positive, however, variable reactivity may be seen with chromogranin and synaptophysin. The majority of cases would however be expected to be at least synaptophysin positive. It is now known that ENB is distinct from the Ewing sarcoma family of tumors. 15 ENB should therefore be negative for the antibody 013 (CD99), which is directed against the Ewing sarcoma-associated MIC2 antigen. Basal cells in the olfactory epithelium have been identified to express neural cell adhesion molecule (NCAM), and the human homologue of the Drosophila achaete-scute (MASH) gene complex. 2 Carney et al 16 identified expression of the human achaete-scute 1 (hASH) gene in ENB, which is the human homologue of MASH. Human achaete-scute homologue gene 1 has been shown to play a crucial role in endocrine/neuroendocrine determination and differentiation in normal development of the nervous system, as well as malignancies including small cell carcinoma of the lung and prostate, neuroblastoma, and medullary carcinoma of the thyroid. 17 Mhawech et al 18 were able to identify hASH1 mRNA using RT-PCR, in ENB, paving the way for future molecular diagnostic developments in the identification and diagnosis of ENB. A better understanding of the genetic and molecular mechanisms underlying the development of ENB will undoubtedly improve our ability to predict prognosis. In current clinical practice, however, staging and predicting outcomes Figure 1 With a median follow-up of 56 months, the 5-year overall and disease-specific survival rates calculated by the Kaplan-Meier method were 78% and 83% respectively.
for ENB is based on assessment of the anatomic extent of the tumor. The Kadish system
19 is one such staging paradigm that was proposed based on observations in a very small number of patients. The categorization into three stages had to be crude because cross-sectional anatomic imaging was not available at the time. Modern day imaging techniques including computed tomography (CT) and magnetic resonance imaging (MRI) allow very precise delineation of anatomy and mapping of tumor extent, and as a result several other staging systems have been proposed.
20-23
Radiologic imaging is crucial in not only estimating the extent of disease, but also in planning treatment. CT and MRI generally complement each other, and should be used to examine specific issues such as bone involvement, inflammatory disease versus tumor, intraorbital or intracranial extension. Thin-section contrast-enhanced axial and coronal CT scan is generally the initial imaging modality since it is a quick examination that allows for the most accurate assessment of the bony structures of the paranasal sinuses and skull base (►Fig. 2A). Staging of the tumor can be accomplished Craniofacial Resection for Esthesioneuroblastoma Patel et al. 213
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based on local extension into the paranasal sinuses and beyond (►Fig. 2B-D). Early bone erosion can be difficult to appreciate on MRI scan but is readily detected on CT (►Fig. 3A, B). ENB can occasionally exhibit intratumoral calcification which is easily appreciated on CT but not on MRI (►Fig. 4). Differentiating tumor from postobstructive inflammatory changes in the paranasal sinuses may be difficult on CT, but is generally easy on MRI, particularly on the T2-weighted sequence (►Figs. 3B and 5). MRI scans are also helpful in delineating intraorbital extension (►Fig. 6A, B). Subtle intracranial extension may be confirmed only at surgery, but dural enhancement (►Fig. 7) and brain edema are reliable radiological signs. The presence of cysts at the periphery of the intracranial component of tumor is an uncommon but characteristic feature of ENB (►Fig. 7). Our analysis may have been affected by the fact that Kadish stage stratification into stage A versus B was not possible because the precise extent of anatomic involvement was not available in 33 patients (22%). Patients who are selected for CFR generally have locally advanced tumors and therefore the majority of the patients in our study were staged Kadish C. Within this group of patients, the most powerful anatomic predictor of outcome was intracranial extension. Patients who had intracranial extension of ENB were three times more likely to recur or die compared with those that did not have involvement of the dura or brain. Intraorbital extension, on the other hand, predicted for worse RFS but was not an independent predictor of survival. This observation may be related to the possibility that variable thresholds for performing orbital exenteration may be in practice at the contributing institutions. As a general rule, orbital preservation is possible if oncologic resection with meaningful postoperative eye function is achievable in patients who have tumor involvement of bone or periosteum without gross invasion of the intraorbital contents. Preservation of the orbit in patients with skull base tumors [24] [25] [26] has been a matter of some controversy, and is not without functional consequence. 26, 27 The rate of local recurrence in the orbit in these patients has been reported to be low, 25, 28 and as our analysis demonstrates, although orbital involvement was a significant predictor of recurrence, it did not significantly alter survival. While details of salvage therapy were not available for analysis, our observations may be explained by the possibility that local recurrence in ENB after orbital preservation may still be surgically salvageable so that eventual survival outcomes remain unaffected. Careful patient selection is crucial in achieving satisfactory outcome after CFR. In spite of advances in preoperative assessment, intraoperative technique and postoperative care about one-third of patients develop complications, as has been reported previously. [29] [30] [31] [32] The mortality rates of the procedure are, however, low. Various treatment combinations have been reported for treatment of ENB. On the whole, outcomes after primary nonsurgical treatment have been worse than those after CFR. [33] [34] [35] Postoperative adjuvant radiation therapy (PORT) has been reported to significantly improve local control 21 in retrospective comparisons. In our cohort, recurrence and survival rates in patients who received PORT were not significantly different from those that did not (5-year RFS: 64.6 vs. 64.0%; 5-year DSS and OS: 81.1 vs. 83.9%). These comparisons are based on retrospective data and it may be argued that patients who are selected for PORT based on a higher estimated risk of recurrence constitute a more aggressive population compared with the group that did not require PORT. In spite of this selection bias, there was only a marginal difference in outcomes in the two groups, and it is possible that PORT may have played a role in improving outcomes in the high-risk group of patients in which it was deemed necessary. The presence of close or positive surgical margins is a common indication for PORT in tumors of the head and neck. Most patients who require CFR for ENB have locally advanced tumors and although the incidence of close or positive margins in our study was 28%, PORT was used in 47% of the patients. If the fact that 34% of patients had been treated with previous radiation therapy and were therefore not eligible for PORT after CFR is taken into account, it is easy to see that the decision for PORT is also influenced by factors other than the status of the surgical margins. Wide resection of these tumors in the conventional sense is generally not achievable because of constraints imposed by the anatomy of the skull base. Therefore, PORT must be considered in the management of most patients with ENB who require CFR. Systemic chemotherapy has been recommended in the multimodality management of ENB.
36-39 Neoadjuvant chemotherapy has been used at the University of Virginia for patients with Kadish C tumors and an 8-year disease-free survival rate of 80.4% has been reported.
40
In spite of aggressive surgical resection in the form of CFR and PORT when indicated or feasible, the 5-year recurrence rate in our patients was 36%. The difficulty in ensuring recurrence-free survival is typical of ENB and is well recognized. Based on the information available in our collaborative dataset, it was not possible to analyze the patterns of recurrence. Attempts have been made to review the literature and estimate patterns of failure in ENB. 2, 41 An accurate estimation Figure 4 Coronal computed tomography scan of the sinuses (bone window) shows intratumoral calcification in an esthesioneuroblastoma of the right nasal cavity. of recurrence patterns is difficult from review of the literature because of small numbers of patients in individual reports, questionable histological diagnosis, heterogeneity in treatment, variable follow-up, and methodological differences in reporting outcomes. Local recurrence after CFR has been reported in 10 to 20% of the patients. 43, 44 . It has also been noted that nodal metastases tend to occur years after initial treatment and that salvage neck dissection is effective in the management of these patients. 40, 43 The role of elective neck treatment has been debated in the literature with proponents of elective neck irradiation 33,45 citing reduced neck metastases. However, none of these reports comment on the impact of elective neck management on survival, and even institutions that have routinely used elective neck irradiation for ENB report disease-specific and overall survival rates that are lower than those reported in the current report or in other studies from authors that do not advocate routine elective neck management.
43
Our study has some obvious deficits that are inherent to this approach of data collection and analysis. 9 As with all other studies that include patients treated over extended time periods without review of pathology material and confirmation of reported histological diagnosis, our study is also susceptible to the possibility that patients with other histological types may have been included under the mistaken diagnosis of ENB. In addition, the duration of follow-up after initial treatment for our cohort was relatively short considering the observation that these patients remain at risk for late recurrences. Nevertheless, the larger number of patients available for analysis has allowed us to identify independent predictors of outcome based on multivariate analysis which has not been possible until now because of lack of sufficient numbers in smaller reports from individual institutions.
Conclusion
This collaborative analysis of patients treated at various institutions across the world demonstrates the efficacy of CFR in the management of ENB. Intracranial extension of disease and complete surgical excision are independent prognostic predictors of outcome. 
